17/08/2026 Argenx announced positive results from the phase 3 ALKIVIA study of efgartigimod in autoimmune myositis Argenx announced positive results from the phase 3 ALKIVIA study of efgartigimod in autoimmune myositis (Ref) Argenx announced positive topline results from the Phase 3, ALKIVIA/ NCT05523167 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. The study met its primary endpoint of mean Total Improvement